PMVP (PMV Pharmaceuticals) Moat Score: 5/10 (As of Jul. 03, 2026)


PMVP PMV Pharmaceuticals Inc PMVP
34 GF Score
Price $1.23
! 2 Warning Signs
View Full Analysis

What is PMV Pharmaceuticals Moat Score?

PMV Pharmaceuticals PMVP -1.61% 34 Moat Score is 5 as of Jul. 03, 2026. GuruFocus rates PMVP with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,399 Biotechnology companies, PMV Pharmaceuticals ranks better than 96.71% on this metric.

PMV Pharmaceuticals has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

PMV Pharmaceuticals has Narrow Moat: PMV Pharmaceuticals has a solid narrow moat due to its valuable intellectual property and R&D capabilities. However, it lacks market leadership and strong brand strength, limiting its competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PMV Pharmaceuticals might have Narrow Moat - Solid narrow moat.

PMV Pharmaceuticals  (NAS:PMVP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PMV Pharmaceuticals Moat Score Related Terms

PMVP vs MNOV, TCRX, BSEM: Moat Score Comparison

For the Biotechnology subindustry, PMV Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PMV Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PMV Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where PMV Pharmaceuticals's Moat Score falls into.


PMVP
34GF Score
PMV Pharmaceuticals Inc PMVP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
PMV Pharmaceuticals (PMVP) has a Moat Score of 5 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, PMV Pharmaceuticals ranks #46 out of 1399 companies in the Biotechnology industry, placing it in the top 3.3%.
Is PMV Pharmaceuticals' Moat Score too high?
PMV Pharmaceuticals' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. PMV Pharmaceuticals' value of 5 is 150% above this industry median. Based on the distribution chart, PMV Pharmaceuticals ranks #46 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PMV Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does PMV Pharmaceuticals' Moat Score compare to MNOV and TCRX?
According to the Biotechnology industry distribution chart, PMV Pharmaceuticals ranks #46 out of 1399 companies for Moat Score. This places PMV Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. PMV Pharmaceuticals' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PMV Pharmaceuticals's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PMV Pharmaceuticals's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PMV Pharmaceuticals stock overvalued right now?
PMV Pharmaceuticals (PMVP) has a current Moat Score of 5. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. PMV Pharmaceuticals' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For PMV Pharmaceuticals (PMVP), the current Moat Score is 5 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PMV Pharmaceuticals Business Description

Address 400 Alexander Park Drive, Suite 301, Princeton, NJ, USA, 08540
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
34GF Score

Get the complete analysis for PMVP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.23
Price